| TRAP1 (TNF Receptor-Associated Protein 1) |
|---|
| Gene | [TRAP1](/genes/trap1) |
| UniProt ID | [Q12931](https://www.uniprot.org/uniprot/Q12931) |
| PDB | 4IYS, 5YKO, 6Z1V |
| Molecular Weight | 75.5 kDa |
| Localization | Mitochondrial matrix, ER, plasma membrane |
| Family | Hsp90 family, mitochondrial Hsp90 paralog |
| Disease | Cancer, PD, AD, Neuroprotection |
TRAP1 (TNF receptor-associated protein 1), also known as Hsp75, is a mitochondrial member of the heat shock protein 90 (Hsp90) family. Unlike cytosolic Hsp90, TRAP1 is primarily localized to mitochondria where it regulates protein folding, oxidative phosphorylation, and mitochondrial quality control. TRAP1 has emerged as a neuroprotective protein in Parkinson's disease and other neurodegenerative conditions.
TRAP1 shares structural homology with Hsp90:
- N-terminal domain (NTD): Contains ATP-binding pocket
- Middle domain (MD): Client protein binding
- C-terminal domain (CTD): Dimerization interface
- Mitochondrial targeting sequence: N-terminal, cleaved after import
Key structural features:
- Forms homodimers via C-terminal domain
- ATPase activity drives conformational changes
- Lacks the charged linker region present in Hsp90
- Unique substrate specificity compared to Hsp90α/β
TRAP1 has multiple mitochondrial functions:
- Protein Folding: Chaperone for mitochondrial proteins
- OXPHOS Regulation: Modulates Complex I and IV activity
- ROS Protection: Reduces reactive oxygen species production
- Bioenergetics: Shifts metabolism from oxidative to glycolytic
- Apoptosis Regulation: Interacts with cyclophilin D to inhibit mPTP opening
- Mitochondrial Dynamics: Affects fission/fusion balance
TRAP1 in the neuroprotection pathway:
- Phosphorylated by PINK1 at S228 → Enhanced activity
- Reduces ROS from Complex I
- Protects dopaminergic neurons
TRAP1 is a key neuroprotective factor in PD:
PINK1-Parkin pathway:
- PINK1 phosphorylates and activates TRAP1
- TRAP1 reduces oxidative stress
- Compensates for PINK1/Parkin deficiency
- Loss of TRAP1 increases PD vulnerability
Protective mechanisms:
- Reduces Complex I ROS production
- Maintains mitochondrial membrane potential
- Prevents cytochrome c release
- Inhibits mPTP opening via cyclophilin D
- Stabilizes respiratory chain components
TRAP1 deficiency:
- Increased susceptibility to MPTP/MPP⁺ toxicity
- Enhanced α-synuclein aggregation
- Accelerated dopaminergic neuron loss
TRAP1 in AD:
- Aβ toxicity: TRAP1 may protect against Aβ-induced mitochondrial dysfunction
- Reduced expression: Observed in AD brain mitochondria
- Complex I protection: May preserve OXPHOS function
TRAP1 is overexpressed in many cancers:
- Promotes the "Warburg effect" (glycolytic shift)
- Protects from apoptosis
- Target for cancer therapy (TRAP1 inhibitors)
- Must balance neuroprotection vs. oncogenic effects
| Strategy |
Mechanism |
Status |
| TRAP1 activators |
Enhance chaperone activity |
Preclinical |
| Mitochondrial Hsp90 inhibitors |
(Cancer context) |
Preclinical |
| PINK1-TRAP1 axis |
Upstream activation |
Research |
| Mitochondria-targeted antioxidants |
Complementary |
Clinical |
Therapeutic considerations:
- TRAP1 activation: Neuroprotective, but may promote cancer
- Selective targeting to brain needed
- Combination with mitochondrial enhancers